Latest news with #Humacyte
Yahoo
5 days ago
- Business
- Yahoo
Humacyte, Inc. (HUMA) Stock Dips While Market Gains: Key Facts
Humacyte, Inc. (HUMA) closed the most recent trading day at $2.21, moving -4.33% from the previous trading session. This change lagged the S&P 500's daily gain of 0.73%. At the same time, the Dow added 0.18%, and the tech-heavy Nasdaq gained 1.21%. Shares of the company have depreciated by 10.12% over the course of the past month, underperforming the Medical sector's loss of 2.44%, and the S&P 500's gain of 0.47%. Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings disclosure. The company is forecasted to report an EPS of -$0.15, showcasing a 44.44% upward movement from the corresponding quarter of the prior year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of -$0.17 per share and a revenue of $8.77 million, indicating changes of +83.81% and 0%, respectively, from the former year. Investors should also pay attention to any latest changes in analyst estimates for Humacyte, Inc. Recent revisions tend to reflect the latest near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Right now, Humacyte, Inc. possesses a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 144, this industry ranks in the bottom 42% of all industries, numbering over 250. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humacyte, Inc. (HUMA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
25-07-2025
- Business
- Yahoo
Humacyte, Inc. (HUMA) Stock Falls Amid Market Uptick: What Investors Need to Know
Humacyte, Inc. (HUMA) closed the most recent trading day at $2.67, moving -2.2% from the previous trading session. This change lagged the S&P 500's daily gain of 0.07%. Meanwhile, the Dow lost 0.7%, and the Nasdaq, a tech-heavy index, added 0.18%. Shares of the company witnessed a gain of 24.66% over the previous month, beating the performance of the Medical sector with its gain of 2.39%, and the S&P 500's gain of 5.71%. Investors will be eagerly watching for the performance of Humacyte, Inc. in its upcoming earnings disclosure. In that report, analysts expect Humacyte, Inc. to post earnings of -$0.15 per share. This would mark year-over-year growth of 44.44%. Regarding the entire year, the Zacks Consensus Estimates forecast earnings of -$0.17 per share and revenue of $8.77 million, indicating changes of +83.81% and 0%, respectively, compared to the previous year. Investors should also note any recent changes to analyst estimates for Humacyte, Inc. Such recent modifications usually signify the changing landscape of near-term business trends. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system. Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. At present, Humacyte, Inc. boasts a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 94, positioning it in the top 39% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Be sure to use to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humacyte, Inc. (HUMA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
16-07-2025
- Business
- Yahoo
Why Humacyte, Inc. (HUMA) Dipped More Than Broader Market Today
In the latest close session, Humacyte, Inc. (HUMA) was down 7.69% at $2.28. The stock trailed the S&P 500, which registered a daily loss of 0.4%. Meanwhile, the Dow lost 0.98%, and the Nasdaq, a tech-heavy index, added 0.18%. The company's shares have seen an increase of 2.49% over the last month, surpassing the Medical sector's loss of 1.56% and falling behind the S&P 500's gain of 4.97%. The investment community will be closely monitoring the performance of Humacyte, Inc. in its forthcoming earnings report. The company is expected to report EPS of -$0.15, up 44.44% from the prior-year quarter. Looking at the full year, the Zacks Consensus Estimates suggest analysts are expecting earnings of -$0.17 per share and revenue of $8.77 million. These totals would mark changes of +83.81% and 0%, respectively, from last year. Investors should also note any recent changes to analyst estimates for Humacyte, Inc. These latest adjustments often mirror the shifting dynamics of short-term business patterns. As such, positive estimate revisions reflect analyst optimism about the business and profitability. Our research shows that these estimate changes are directly correlated with near-term stock prices. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Humacyte, Inc. currently has a Zacks Rank of #3 (Hold). The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 77, this industry ranks in the top 32% of all industries, numbering over 250. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Ensure to harness to stay updated with all these stock-shifting metrics, among others, in the next trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humacyte, Inc. (HUMA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
01-07-2025
- Business
- Yahoo
Humacyte, Inc. (HUMA) Stock Declines While Market Improves: Some Information for Investors
In the latest trading session, Humacyte, Inc. (HUMA) closed at $2.09, marking a -1.42% move from the previous day. This change lagged the S&P 500's daily gain of 0.52%. Meanwhile, the Dow gained 0.63%, and the Nasdaq, a tech-heavy index, added 0.48%. Prior to today's trading, shares of the company had lost 20.6% lagged the Medical sector's gain of 1.88% and the S&P 500's gain of 4.27%. Analysts and investors alike will be keeping a close eye on the performance of Humacyte, Inc. in its upcoming earnings disclosure. In that report, analysts expect Humacyte, Inc. to post earnings of -$0.15 per share. This would mark year-over-year growth of 44.44%. For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.18 per share and revenue of $8.77 million, which would represent changes of +82.86% and 0%, respectively, from the prior year. Investors might also notice recent changes to analyst estimates for Humacyte, Inc. These revisions typically reflect the latest short-term business trends, which can change frequently. Hence, positive alterations in estimates signify analyst optimism regarding the business and profitability. Empirical research indicates that these revisions in estimates have a direct correlation with impending stock price performance. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system. The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed an unchanged state. Humacyte, Inc. is holding a Zacks Rank of #2 (Buy) right now. The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 88, this industry ranks in the top 36% of all industries, numbering over 250. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Keep in mind to rely on to watch all these stock-impacting metrics, and more, in the succeeding trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humacyte, Inc. (HUMA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
26-06-2025
- Business
- Yahoo
Humacyte, Inc. (HUMA) Stock Moves -1.79%: What You Should Know
In the latest close session, Humacyte, Inc. (HUMA) was down 1.79% at $2.19. Meanwhile, the Dow lost 0.25%, and the Nasdaq, a tech-heavy index, added 0.31%. The company's stock has dropped by 10.08% in the past month, falling short of the Medical sector's gain of 3.46% and the S&P 500's gain of 5.05%. The investment community will be paying close attention to the earnings performance of Humacyte, Inc. in its upcoming release. On that day, Humacyte, Inc. is projected to report earnings of -$0.15 per share, which would represent year-over-year growth of 44.44%. For the entire fiscal year, the Zacks Consensus Estimates are projecting earnings of -$0.18 per share and a revenue of $8.77 million, representing changes of +82.86% and 0%, respectively, from the prior year. It's also important for investors to be aware of any recent modifications to analyst estimates for Humacyte, Inc. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook. Our research suggests that these changes in estimates have a direct relationship with upcoming stock price performance. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model. The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has remained steady. Humacyte, Inc. is holding a Zacks Rank of #2 (Buy) right now. The Medical - Biomedical and Genetics industry is part of the Medical sector. Currently, this industry holds a Zacks Industry Rank of 83, positioning it in the top 34% of all 250+ industries. The Zacks Industry Rank assesses the strength of our separate industry groups by calculating the average Zacks Rank of the individual stocks contained within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Remember to apply to follow these and more stock-moving metrics during the upcoming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Humacyte, Inc. (HUMA) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
